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Abstract
Purpose: Triple negative breast cancer (TNBC) is an aggressive subtype of breastcancer with poor prognosis despite the high rates of response to chemotherapy.We aim to study the clinical features, factors influencing recurrence and survivaloutcomes of TNBC patients. Methods: We retrospectively studied the charts ofpatients with biopsy proven TNBC treated at The Clinical Oncology DepartmentAin-Shams University between 2009 and 2012. Results: One hundred and fortyfive patients fulfilled the eligibility criteria. The incidence of TNBC was 10.5% -15% with a mean of 12% of all breast cancer patients. The follow-up durationranged from six months to four years. The age range was 26 to 78 years. Infiltratingductal carcinoma represented 93.1% of the pathologic types. 87% of patients werefree of metastases (M0) at presentation. Clinical stages II and III represented 38and 39.5% of the patients. 66% of patients had modified radical mastectomy.Following surgery, 77.5% of patients received adjuvant chemotherapy while 61%of the patients had adjuvant radiation therapy. Anthracyclines based chemotherapywas given to 52% of patients. Disease-free survival (DFS) of the M0 patients at 20and 30 months was 92% and 80% respectively. Relapse occurred in 23% of M0patients. After a mean duration of DFS of 15.1 months, the most common sites ofmetastases for relapsed M0 patients were pulmonary (44.8%), bone (41.4%), andlocoregional (13.8%). The median overall survival (ORS) of patients was 18 months(1 - 45 months), whereas for the M1 group of patients the median ORS was 9months (2 - 29 months). Conclusion: The incidence, pathological characteristics,and clinical behavior of TNBC were similar to what is mentioned in the literature.Adding taxanes to the chemotherapy protocols and using postoperativeradiotherapy were both associated with a significant increase in the mean period ofDFS, while did not significantly affect the ORS.
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1. IntroductionBreast Cancer is still the most common malignancy inwomen worldwide, including Egypt (Cancer registry inEgypt). TNBC (Triple negative breast cancer) isfrequently identified by conventional immune-histochemical techniques, as these tumors lack stainingfor the estrogen receptor (ER), progesterone receptor(PR), and the human epidermal growth factor (HER2).1The St. Gallen international expert consensus 2011proposed a new classification system for breast cancerbased on its division into five subgroups, namely;normal-like, basal, luminal A&B and HER-2 enriched. AClaudin- low subtype is another described molecular
subtype referring to tumors showing features ofmesenchymal and mammary stem cells.2 The criteria toidentify subtypes were further recently refined at the2013 conference, in that moderate or a strongexpression of PR and Ki - 67 level were both recognizedas being important to the surrogate definition of a“Luminal A-like” disease. According to these criteria, thesubtypes in question have been defined as: Luminal A –ER positive, HER2 negative, Ki - 67 low, and PR high;Luminal B (HER2 negative) – ER positive, HER2negative, and either Ki - 67 high or PR low; LuminalB-like (HER2 positive) – ER positive, HER2 overexpressed or amplified, any Ki - 67, and any PR; HER2
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positive – HER2 over - expressed or amplified, ER andPR absent; and triple negative – ER and PR absent andHER2 negative.3
TNBC patients have a higher risk of metastases and pooroverall survival because TNBC is found to be correlatedwith mutations of BRCA1 gene, over expression ofoncoytogenic kinases such as human epidermal growthfactor receptor 2, vascular endothelial growth factor - A,insulin-like growth factor - 1 (IGF - 1) / IGF receptor andtransforming growth factor - B1.4 These molecularfeatures may have implications for chemotherapysensitivity to platinum and other directly DNA -damaging agents. Using gene expression analysis,Lehmann et al identified six TNBC subtypes namely;basal - like (BL1 & BL20), an immunomodulatory (IM), amesenchymal (M), a mesenchymal stem - like (MSL) anda luminal androgen receptor (LAR) subtype.5TNBC is a clinically challenging subtype which accountsfor about 9-21% of all breast cancers, including patientswith stages, I – IV.6 Compared to other types of breastcancer, TNBC is associated with poor prognosis andoverall survival.1, 7, 8 TNBC patients tend to be of youngerage less than 50 years.1, 9 TNBC tumors have a shortermedian time to relapse and death. TNBC is often locallyadvanced and of high grade.1 The patients haveincreased risk of local recurrence and metastases,mainly in the lung, brain and soft tissue.10,11,7,8 TNBC ismore chemosensitive, and have higher rates ofpathological complete remission following neoadjuvantchemotherapy than in other breast cancer types.8 Theadjuvant chemotherapy is usually recommended inTNBC and should include anthracyclines, taxanes and analkylating agent.12 On the other hand TNBC lackstargeted therapies, and patients do not benefit from anti- estrogen hormonal therapy or trastuzumab.1The aim of this retrospective analysis is to study theclinical characteristics, the prognostic factors ofrecurrence, disease free survival and overall survival inEgyptian TNBC patients treated at the Department ofClinical Oncology, Ain-Shams University.
2. Methods and MaterialsWe analyzed the institutional medical records, andidentified patients who were histopathologicallydiagnosed with triple negative breast cancer andunderwent primary treatment at The Clinical OncologyDepartment Ain - Shams University between 2009 and2012. After obtaining approval from the InstitutionalReview Board at Ain - Shams University Hospitals, aretrospective chart review of patients' demographics,clinical and pathological data was performed.Treatment, follow-up and survival data were obtainedfrom the patients’ records. One hundred and forty fivepatients fulfilled the eligibility criteria which are 18
years or older, immunohistochemistry (IHC) negativeexpression of ER and PR, and negative HER - 2 neuexpression or HER - 2 neu 1+ or 2+ expression on IHCaccompanied by a negative fluorescence in situhybridization (FISH) result.
2.1 Statistical analysisData were revised, coded, tabulated and analyzed usingthe Statistical Software Package for the Social Sciences,for Windows version 18.0 (SPSS / PASW, Inc., 2009,Chicago, IL). Descriptive statistics (mean and standarddeviation) were used to evaluate the DFS of the non -metastatic group of patients, and to evaluate the ORS ofboth metastatic and non-metastatic groups. Chi-squaretests were used to assess differences between the DFSand ORS using categorical variables. The overall survivaltime was calculated in months from the date of diagnosisbased on breast biopsy to the date of death or lastfollow-up. The DFS in months was calculated from theend of the primary treatment until the last date thepatient survived without symptoms or signs. UnivariateKaplan - Meier survival curves were plotted, and the log- rank test was used to determine if differences werestatistically significant. Statistical significance wasdefined as alpha less than 0.05.
3. ResultsWe studied 145 out of the 154 patients diagnosed withTNBC who presented to our department over four -years period where 9 patients had incomplete data intheir charts (Table 1). The mean age at diagnosis was 52years. A positive family history was detected in (7.6%)11 / 145 of TNBC patients (Table 2).The most common histopathologic type was infiltratingductal carcinoma (93.1%) 135 / 145. Most of the tumorswere grade II, 73.7% (107 / 145). More than half of thetumors were T2 lesions 52.4% (76 / 145). 96 out of 145patients had positive lymph nodes (N1, N2, and N3) atdiagnosis (66.2%). Majority of patients were diagnosedwith stage II and III breast cancer [38% (55 / 145) and40% (58 / 145) respectively] (Table 3). Most of thepatients had modified radical mastectomy (76%) 110 /145, and the rate of breast conservative surgery wasonly 11.7% (17 / 145) patients because many patientshad stage III cancer (Table 4). Adjuvant chemotherapywas administered in 77.5% (112 / 145) of patients, ofwhom 25 patients 22.3% (25 / 112) developedrecurrence. 14 patients out of 145 (9.7%) receivedneoadjuvant chemotherapy, with recurrence in 4patients (28.6%). 89 of 145 patients (61.3%) receivedadjuvant radiotherapy, followed by recurrence in only19 / 89 patients (21.3%). Anthracyclines - basedregimens were used as adjuvant or neoadjuvant in(52.4%) 76 / 145 of patients.
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Table1: Summary of breast cancer registration in Ain-Shams Oncology Department from 2009 to 2012Year No. of allcancerpatients No. ofbreastcancerpatients
No. ofTNBCpatients % of TNBCof all breastcancerpatients2009 1441 315 47 15 %2010 1536 333 40 12 %2011 1563 294 31 10.5 %2012 1489 324 36 11%Total 6029 1266 154 12%
Table 2: Patients characteristics (n= 145)Variable No. of patients %Age at initial diagnosis, yearsMeanRange 5227-78Menopausal historyPremenopausalPostmenopausalPerimenopausal 70705 48.348.33.4Family HistoryPositiveNegativeUnavailable 111286 7.6894
The DFS for the M0 patients (126) at 20 and 30 monthswas about 92% and 80% respectively (Figure 1). After amean period of disease - free survival (DFS) of 15.1months, 29 patients out of 126 (23%) relapsed. Themost common sites of relapse were the lung (13patients, 44.8%), bone (12 patients, 41.4%), andlocoregional (4 patients, 13.8%) (Table 8). The overallsurvival of both M0 and M1 patients at 20 months and30 months was about 98% and 88% respectively (Figure2). The median ORS for the M0 group of patients was 18months (1 - 45 months), whereas for the M1 group ofpatients the median ORS was 9 months (2 - 29 months)(Table 5).Except for tumor stage which had direct effect on therecurrence and overall survival (P < 0.05), univariateanalysis showed that all other risk factors had nostatistically significant relationship to either recurrenceor overall survival (Tables 6, 7). Patients with stages 0and I had no recurrence compared to patients withadvanced stages. Similarly, the overall survival ofpatients with early stages was better than withadvanced stages as shown in Table (5). The diseasestage, the type of chemotherapy and the adjuvantradiation therapy had direct statistically significanteffect on the DFS (P < 0.05) (Table 6).
Table 3: Tumor characteristics (n=145 patients)Variable No of  patients %Histologic typeInfiltrating ductal carcinomaInfiltrating lobularcarcinomaDuctal carcinoma in situ
13591 93.16.20.7
Histologic gradeIIIIIIUnavailable
41072311
2.773.7167.6Tumor sizeTisT1T2T3T4Unavailable
114763897
0.79.752.426.26.24.8Nodal involvementN0N1N2N3Unavailable
424034227
2927.523.5155StagingStage 0Stage 1Stage 2Stage 3Stage 4Unavailable
195558193
0.76.33840132Metastasis at diagnosisM0M1 12619 8713
Figure 1: Disease Free Survival of M0 triple negative breastcancer patients at Department of Clinical Oncology, AinShams University (2009-2012).
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Figure 2: Overall survival of both M1 and M0 triplenegative breast cancer patients at Department of ClinicalOncology, Ain Shams University (2009-2012).
Table 4: Treatment of M0 and M1 (n =145)Variable No. of patients %SurgeryModified radical mastectomyConservativeSimple mastectomyOnly biopsy
11017711
7611.74.87.5ChemotherapyAdjuvantNeoadjuvantPalliativeUnavailable
11214163
77.29.7112.1The chemotherapy regimenAnthracyclines basedSequentialAnthracyclines/TaxanesOther regimensUnavailable
766063
52.441.44.12.1RadiotherapyAdjuvantPalliativeNot given 891046 61.3731.7
Table 5: Treatment outcomeVariable No. of patients %Disease free survival for M0patients (n =126)No recurrenceRecurrence 9729 7723Progression free survival for M1patients (n = 19)Progression or newmetastatic siteNo Progression or newmetastatic site
712 36.863.2Overall survival for M0 (n =126) 115 91.26Overall survival for M1 (n =19) 13 68.4
4. DiscussionThe current study is a retrospective review of 145patients with TNBC in our institution over a 4-yearperiod (2009 - 2012). It is one of the few studies ofTNBC in non - Western countries. In our study, the rateof TNBC was 12%, which is comparable to other studies(9 – 21%) in non - Western countries10, 13, 14, and inWestern countries.15, 11,6,16 Triple - negative breasttumors have been characterized by several aggressiveclinicopathologic features including onset at youngerage, higher mean tumor size, higher-grade tumors, and,in some cases, a higher rate of node positivity.1, 17The mean age at diagnosis in this study is 52 years,similar to the mean age at presentation documented bymany studies.18,19,1,20 Some studies showed differentmean ages of TNBC patients 44 - 45 years in Korea andTurkey21,22, and 56 years in Japan.23Ghosn et al10 and Fakhoury24 reported a positive familyhistory in 10% of patients with TNBC in Lebanoncompared with 1% of patients with breast cancer whenall phenotypes are included. In our study, a positivefamily history was documented in 7% of patients.Similar incidence of less than 10% was found by Rais et
al.13 Higher incidence of positive family history wasdocumented by other studies, both Kwan et al, andFayaz et al20,2520% and 28% in Phipps et al.26The histological characteristics in this current studyshowed that invasive ductal carcinoma represented93.3% in accordance with 90% in many studies.27-32Invasive ductal carcinoma was most predominant inSingapore and Japan (93% and 95%, respectively).23,33Invasive lobular carcinoma was interestingly reported in2% of TNBC patients in Singapore23, 4% in Kuwait25,2.3% in Italy34 vs. 6% in our study. This may representthe pleomorphic subtype of lobular carcinoma.35 Triplenegative breast cancers are mainly high- grade tumorswith high mitotic index and marked cellularproliferation.1, 21, 28, 36-38 Most studies reportedpredominance of high histologic grade that ranged from55-62%. Contrary in our study, grade II tumorsrepresented 74%, while grade III was 16%.The aggressiveness of this type of breast cancer and itshighly proliferating nature mean that it also tends to bediagnosed at a later stage.18, 39 Our analysis found thatstages 0 – I represented 45% while stages III and IVrepresented 52.5%. This is comparable to somepublications, which reported 34% stage III vs. 15% stageI in a study by Pogoda et al40, 8% stage I vs. 28% stage IIIin a study by Rais et al.13 Fayaz et al25 reported 56% ofpatients with stages, I and II while stage III represented37 %. Stark et al41, studied a series of 1236 patients withinvasive ductal carcinoma, they concluded that womenwith stages III and IV were 16 times more likely to havetriple - negative tumors than those with early stages
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[odds ratio (OR) 16.4; 95% confidence interval (CI): 7.8– 34.2].Triple - negative breast cancers are commonly of largesize at presentation.29, 36-38, 42-45 Tumor size was the mostrelevant prognostic factor for survival in some studies.In a study by Pogoda et al, the hazard ratio of recurrencein patients with a tumor > 5 cm was 16 times higherthan in patients with tumor > 2 cm. The authors alsofound a higher hazard for death in patients with largetumors (HR = 8.21 in tumors > 5 cm).40 Similarly, Hammet al reported that the tumor size was the mostimportant prognostic factor.15 Moreover, tumors < 2 cmwith negative nodes were documented to have a highrecurrence rate.38,45 The current study documentedpredominance of T2 tumors.The detection of positive lymph nodes at presentation inTNBC patients is interestingly contradictory in differentstudies. Dent et al1 found that the rate of node positivitywas slightly higher in node positive TNBC comparedwith other types of breast cancer (54.6% versus 45.6%,respectively; P = 0.02). Similar results of positive lymphnodes were reported by Fayaz et al and Ghosn et al(58and 50% respectively).25,10 Lin et al and related studiesdemonstrated that TNBC was less likely to be lymphnode positive (38 and 41%, respectively).17,7 A muchlower incidence of positive lymph nodes was detected inJapanese patients by Ishikawa et al.33 In the currentstudy, positive lymph node was 66% possibly due to thetendency to late presentation of patients in the socialstratum that we treat at our center.Despite the poor clinical outcome and DFS, the moreaggressive clinical course in the metastatic setting, TNBCis sensitive to standard chemotherapy. Chemotherapy isthe standard treatment of TNBC in the adjuvant,neoadjuvant, and metastatic settings due to the lack ofresponse to traditional hormonal therapies and targetedtherapies.1 TNBC patients have a higher pathologiccomplete response (pCR) than non - TNBC, and alsobetter survival compared to TNBC patients who do notachieve pCR.8 The pCR rate was 29% in patients whoreceived neoadjuvant anthracyclines based chemo-therapy and 38% after anthracyclines and taxanescombined treatment.46,47 In another study, two thirds ofpatients received neoadjuvant anthracycline- taxanechemotherapy and only 15% of them achieved pCR;recurrence occurred in almost half of patients in thisgroup.40 Our study, showed that the majority of M0patients (n = 126) received adjuvant chemotherapy(89%) in the form of anthracyclines based regimens(52.3%). There was insignificant difference betweenpatients who received adjuvant vs. neoadjuvantchemotherapy as regards the recurrence status (DFSwas 15.48 months and 11.75 months respectively) andas regards the overall survival, (ORS was 91.07% and92.86%, respectively). Similarly the type of
chemotherapy, whether combined anthracyclines andtaxanes or taxanes alone in M0 patients (n = 126) didnot significantly affect both the DFS (76.67% and77.27% respectively) and the ORS (95% and 87.88%respectively).Triple negative breast cancers have been associatedwith lower disease - free survival, a higherpredisposition to visceral metastases and pooreroutcome when compared to other subtypes of breastcancer.18, 1,48,49 Women with triple negative breastcancer typically tend to develop recurrence during thefirst 3 years after therapy with a rapid declinethereafter; and the majority of deaths occur in the first 5years post treatment. Patients with non - TNBC havemore consistent rates of recurrence.1,8 In both studies byGhosn et al, and Haffty et al10,50, the peak of recurrenceoccurred after 6 - 18 months. Fayaz et al25 reported thepeak of recurrence at 30 months. We observed the samephenomenon where after a mean period of DFS of 15.1months, 29 out of 126 metastases - free patientsdeveloped recurrence. The lung was the most commonsite of metastases followed by bone and locoregionalrecurrence (Table 8). The ORS for the non - metastaticgroup at presentation of patients was 87% (11 / 126),whereas for the metastatic group of patients M1 the ORSwas 31.6% (6 / 19). The Mayo Clinic Study reported anoverall survival at 5 years after surgery of 85% vs. 87%in the present study. In Kaplan et al.6 study, the 5 - yeardisease - free survival and ORS in TNBC patients were84% and 81% respectively. The variable resultsbetween studies may be dependent on the difference instaging of breast cancer, in the present study majority ofpatients were stage II and III, whereas in Kaplan’s studyabout 80% of patients presented with stages, I and II.To date, not a single targeted therapy has been approvedfor the treatment of TNBC, and cytotoxic chemotherapyremains the standard treatment.51 Novel candidatecompounds for TNBC have entered phase II and phaseIII trials and will likely require patient stratificationbefore therapy. Examples of these tailored approachesinclude poly (adenosine diphosphate - ribose)polymerase (PARP) inhibitors for BRCA - mutated TNBC,antiandrogens for androgen receptor (AR) – positiveTNBC, fibroblast growth factor receptor (FGFR)inhibitors for TNBC harboring FGFR amplifications, andgamma - secretase inhibitors for TNBC with mutationsin the PEST domain of NOTCH proteins. Well - designedclinical trials of molecularly targeted therapy fordifferent subgroups of TNBC are necessary.52
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Table 6: Factors influencing recurrence and mean duration of DFS for M0 disease (n=126)Variable Recurrence Norecurrence Totalnumber P value Meanduration ofDFS ± SD P valueStage0IIIIII
00 (0%)6 (11%)22 (38%)
194936
195558 0.002Chemotherapy TypeAnthracyclines/taxanesAnthracyclines 14 (23.3%)15 (22.7%) 4651 6066 0.9 (NS) 19.3± 11.7 0.031
RadiotherapyAdjuvantNo adjuvant 19 (21.4%)10 (27%) 7027 8937 0.5 (NS) 18 ±10.4 0.027SD: standard deviation
Table 7: Factors influencing overall survival (ORS)of M1 andM0 patients (n=145)Alive Dead OS % P valueStage0IIIIIIIV
19525013
00386
1001009586.268.4 0.03
Table 8: Pattern of recurrence in M0 patients (n = 29/126)Site Number %Lung 13 44.8Bone 12 41.4Locoregional 4 13.8PARP enzymes are critical to cell recovery from DNAdamage. When PARP1, the most abundant member ofthe PARP family, is inhibited, double - strand DNAbreaks accumulate and under normal conditions arerepaired via the BRCA pathway-dependent homologousrecombination mechanism.53 The efficacy and safety ofPARP inhibitors are tested in clinical trials in both BRCA- mutated and triple negative breast cancers because ofthe shared clinicopathologic characteristics.54 -56 In asingle arm study olaparib (400 mg orally twice daily)was administered to women with BRCA1 and / orBRCA2 - deficient, advanced breast cancer (of which >50 percent were triple - negative). Olaparib resulted inan overall response rate of 41 percent and PFS of 5.7months. The drug was generally well tolerated with themost commonly reported grade 3 adverse events beingfatigue, nausea, and vomiting.54,57 On the other hand,another study showed that olaparib had no activity in
breast cancer outside of patients with known germlineBRCA mutations, although epithelial ovarian cancerappears to respond similarly regardless of germlinestatus.58The role of cetuximab; an anti - EFGR monoclonalantibody in patients with metastatic TNBC was studied59by comparing cetuximab plus cisplatin versus cisplatinalone. The authors demonstrated an overall betterresponse rate of 20% when compared to a 10% overallbetter response rate with cisplatin alone. Cisplatin pluscetuximab also resulted in longer progression freesurvival (PFS) compared with cisplatin alone (median,3.7 vs. 1.5 months) with a corresponding median OS of12.9 versus 9.4 months. Common grade 3 / 4 adverseevents included acne - like rash, neutropenia, andfatigue. Despite the longer PFS and OS, the trial failed toreach its primary endpoint, which is the overallresponse rate compared to the single regimen.Additionally cetuximab induced diarrhea was a concernwhen added to chemotherapy as carboplatin andirinotecan despite an increased overall response rate inthe TNBC subset of O’Shaughnessy’s phase II trial.60 Thepotential efficacy of anti - EGFR strategies needs furtherinvestigation with more trials.
5. ConclusionThis study documents the clinical experience of TNBC atour institution. The results of the study accord with theliterature data of characteristics of TNBC in terms ofyoung age at presentation, high - grade tumors, latestages at diagnosis, and short disease - free survival. Weacknowledge the limitations of this study inherent tomost retrospective studies, the relatively small sample
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size, and the lack of BRCA gene mutations’ studies due tothe limited financial resources. However, our results areunique to Egypt, are one of the very few studies of TNBCin the Middle East, and represent a single - institutionapproach to patient care.Tumor stage, chemotherapy type and adjuvant radiationtherapy statistically influenced the recurrence and theduration of disease - free survival. In addition, the tumorstage statistically influenced the overall survival of boththe metastatic and non - metastatic TNBC in our study.Unfortunately, TNBC as an aggressive subtype of breastcancer has limited treatment options when it does notrespond to or progresses after the standard and /ortaxanes based regimens. More research should bedirected at identifying molecules and pathways that maybe effective targets for new drugs.
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